Presentation of Adult Stem Cell Study Highlights Promising Application of Autologous Stem Cells for Treatment of Spinal Cord Injury
CHICAGO, Oct. 19 DaVinci Biosciences LLC, of Costa Mesa, CA, announced today the presentation of their safety and feasibility study demonstrating the administration of autologous bone marrow derived stem cells for the treatment of acute and chronic spinal cord injury at Neuroscience 2009, Society for Neuroscience's 39th Annual Meeting, to be held at McCormick Convention Center in Chicago, IL. Rafael Gonzalez, Ph.D., Director of Research and Development for DaVinci Biosciences LLC will present the work during the conference on October 20, 2009 and be available to answer questions regarding the study, following his presentation. "We are excited to share the findings of this study in such a public forum. This study successfully demonstrates not only the safety and feasibility of using autologous adult stem cells for treating spinal cord injuries, but also that the clinical procedure for delivering these cells is safe as well," said Dr. Gonzalez.
The abstract highlights data from 8 patients that underwent the treatment which used stem cells harvested from the patients' own bone marrow to sidestep any immune rejection response, and features the documented evaluations from a 2 year post surgical follow up period. Furthermore, it illustrates new data obtained from 46 patients that participated in the study using stem cells harvested from the patients' own bone marrow. Magnetic resonance imaging data of the spinal cord, obtained from those who were treated, shows morphological changes within the damaged areas. In addition, this study documents the improved function of bladder control, ASIA motor scoring and Barthel scoring. "Although this study was successful, we will build upon the results that we have achieved and the methods we have developed to progress into a larger clinical program. Responsibly, but timely developing ways to improve the quality of life for those affected with injuries or diseases, such as spinal cord injury, is the core of our mission and we are optimistic about the opportunity of conducting future studies in the US," said Dr. Gonzalez.
The presentation will feature data published earlier this year by DaVinci Biosciences in issue 17 (12) of Cell Transplantation, a peer-reviewed scientific journal focused on regenerative medicine. The annual Neuroscience 2009 conference will be held October 17 - 21, 2009 and will be host to an anticipated 30,000 attendees.
About DaVinci Biosciences
DaVinci Biosciences LLC is a privately held company dedicated to advancing therapies that improve the quality of life for individuals suffering from trauma, disease and degenerative disorders. Through independent research and partnerships with universities, medical research institutions, and hospitals, DaVinci Biosciences continues to discover biological breakthroughs relating to and further improving the treatment of degenerative disorders and injury. DaVinci Biosciences is headquartered in Costa Mesa, California. For more information please visit www.dvbiosciences.com.
SOURCE DaVinci Biosciences LLC
You May Also Like